ELTP (Elite Pharmaceuticals) Tariff Resilience Score: 6/10 (As of Jun. 29, 2026)


ELTP Elite Pharmaceuticals Inc ELTP
44 GF Score
Price $0.40
GF Value $0.57
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Elite Pharmaceuticals Tariff Resilience Score?

Elite Pharmaceuticals ELTP +2.62% 44 Tariff Resilience Score is 6 as of Jun. 29, 2026. GuruFocus rates ELTP with a GF Score™ of 44/100 and a GF Value™ of $0.57 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 1,028 Drug Manufacturers companies, Elite Pharmaceuticals ranks better than 91.15% on this metric.

Elite Pharmaceuticals has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Elite Pharmaceuticals has Elite Pharmaceuticals has moderate exposure to tariffs due to its reliance on global supply chains for raw materials. However, its primary market is domestic, reducing direct tariff impact. Historical data shows limited impact from past tariffs, and the company has some pricing power to mitigate costs.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Elite Pharmaceuticals might have Average Resilient.

Elite Pharmaceuticals  (OTCPK:ELTP) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Elite Pharmaceuticals Tariff Resilience Score Related Terms

ELTP vs EBS, NIKA, EOLS: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Elite Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Elite Pharmaceuticals Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Elite Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Elite Pharmaceuticals's Tariff Resilience Score falls into.


ELTP
44GF Score
Elite Pharmaceuticals Inc ELTP
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Elite Pharmaceuticals (ELTP) has a Tariff Resilience Score of 6 as of Jun. 29, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Elite Pharmaceuticals ranks #91 out of 1028 companies in the Drug Manufacturers industry, placing it in the top 8.9%.
Is Elite Pharmaceuticals' Tariff Resilience Score too high?
Elite Pharmaceuticals' current Tariff Resilience Score is 6. Based on the distribution chart, Elite Pharmaceuticals ranks #91 out of 1028 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Elite Pharmaceuticals has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Elite Pharmaceuticals' Tariff Resilience Score compare to EBS and NIKA?
According to the Drug Manufacturers industry distribution chart, Elite Pharmaceuticals ranks #91 out of 1028 companies for Tariff Resilience Score. This places Elite Pharmaceuticals in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Elite Pharmaceuticals's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elite Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Elite Pharmaceuticals (ELTP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.57, compared to a current price of $0.40 — trading 30.7% below its estimated fair value. The current Tariff Resilience Score is 6. Elite Pharmaceuticals' overall GF Score™ is 44/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Elite Pharmaceuticals (ELTP), the current Tariff Resilience Score is 6 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Elite Pharmaceuticals (ELTP) Overvalued in 2026?

Based on GuruFocus' analysis, Elite Pharmaceuticals stock appears to be undervalued. The current stock price of $0.40 is trading 30.7% below its estimated GF Value™ of $0.57. GuruFocus considers Elite Pharmaceuticals to be Possible Value Trap.

Key valuation signals for ELTP:

  • Tariff Resilience Score: 6
  • GF Value™: $0.57 vs. price of $0.40 (30.7% below fair value)
  • GF Score™: 44/100 with 1 warning sign

No single metric tells the full story. See the ELTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Elite Pharmaceuticals Business Description

Address 165 Ludlow Avenue, Northvale, NJ, USA, 07647
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
44GF Score

Get the complete analysis for ELTP

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.40
Price
$0.57
GF Value